Sacubitril/valsartan improves exercise performance in patients with heart failure: a dose-dependent effect
Anno:
2023
Background: Sacubitril/Valsartan therapy has become a cornerstone of heart failure with reduced ejection fraction (HFrEF) pharmacological therapy due to its positive prognostic impact. However, conflicting results have emerged on the effects of sacubitril/valsartan on exercise performance assessed by cardiopulmonary exercise test (CPET). Aim of the study: The aim of…